melanotan 2 dosing: Frequently asked questions

Nausea is the most common side effect of melanotan-2 dosing tanning protocols and occurs in 20–40% of users at doses above 0.25 mg. It typically peaks 1–2 hours post-injection and resolves within 3–4 hours. Mitigation strategies include dosing in the evening before sleep (so nausea occurs during sleep), eating a small protein-containing meal 30–60 minutes before injection, and reducing the dose by 50% for 2–3 days before titrating back up. Persistent nausea beyond 4 hours or vomiting after injection indicates the dose is too high. Reduce to 0.25 mg and reassess tolerance after 3 days.

Uneven pigmentation after melanotan-2 dosing tanning loading maintenance typically results from one of three causes: inconsistent dosing intervals during loading (skipping days or dosing at irregular times), insufficient UV exposure in under-pigmented areas, or naturally lower melanocyte density in those regions. The solution is to extend the loading phase by 3–5 days while ensuring daily UV exposure to all skin areas, then transition to maintenance. Some body regions. Inner arms, abdomen, upper thighs. Have lower baseline melanocyte counts and require longer UV exposure to achieve the same pigmentation depth as face, shoulders, and forearms.

Administer the missed dose as soon as you remember if fewer than 12 hours have passed, then continue your regular schedule the next day. If more than 12 hours have passed, skip the missed dose and resume the following day. Do not double-dose to 'catch up'. Missing 1–2 doses during a 10-day loading phase delays visible pigmentation by 2–3 days but does not compromise the final result. Missing more than 3 doses during loading often produces uneven melanogenesis, requiring an extended loading phase of 12–14 days to achieve uniform pigmentation.

If the vial was at room temperature (20–25°C) for fewer than 8 hours, refrigerate it immediately and continue using it. Peptide degradation at this temperature is measurable but not complete. If it was out for 8–12 hours, the peptide may have lost 20–40% potency; you can continue using it but may need to increase the dose slightly or extend the loading phase. If it was out for more than 12 hours or exposed to temperatures above 30°C, discard the vial. The peptide structure has likely denatured beyond effective use, and continuing to inject it wastes time and produces inconsistent results.

No. Doubling the dose increases side effect severity (nausea, facial flushing, spontaneous erections in male subjects) without proportionally increasing melanogenesis. MT-2's extended half-life means missing one dose during a 10-day loading phase has minimal impact on steady-state plasma levels. If you miss a dose, continue the protocol at standard dosage the following day. The cumulative effect of daily dosing means one skipped injection delays target tan achievement by approximately 1 day, not the full protocol timeline. Subjects who double-dose to 'catch up' report adverse events at 2–3× baseline frequency without meaningful acceleration of pigmentation.

No. The melanogenesis mechanism is identical whether UV stimulus comes from solar radiation or controlled lamp exposure. Inject MT-2 2–4 hours before planned lamp session. Most research-grade UV-B lamps deliver 0.3–0.5 MED per 10–15 minute session, equivalent to midday sun exposure at UV index 6–8. The advantage of lamp use is consistency: you can schedule UV exposure at the same time daily during loading phase, allowing precise injection timing (e.g., inject 10 AM, lamp session 2 PM). Natural sun exposure introduces variability (weather, schedule conflicts) that complicates timing coordination.

You'll still achieve some melanogenesis due to the peptide's 33-hour half-life, but efficiency drops significantly. Plasma MT-2 peaks 4–6 hours post-injection (10 PM–12 AM if injecting at 6 PM), while your planned UV exposure occurs 16–18 hours later when plasma levels have declined past optimal receptor occupancy. Research cohorts following this pattern require 50–70% more total peptide to reach equivalent pigmentation compared to subjects who inject 2–4 hours before UV exposure. If evening injection is unavoidable, plan UV exposure within 12 hours (morning sun the next day) rather than waiting until afternoon.

Melanin degradation follows first-order kinetics with a biological half-life of approximately 14–21 days in epidermal melanocytes. Without continued UV exposure or MT-2 maintenance dosing, visible tan fades 50% in 2–3 weeks and returns to baseline within 6–8 weeks. To preserve pigmentation, transition to maintenance protocol (250–500mcg 2–3× weekly with corresponding UV exposure). Subjects who stop injections abruptly but continue regular UV exposure retain 60–70% of peak pigmentation for 4–6 weeks before gradual fading; those who stop both MT-2 and UV lose pigmentation within 3–4 weeks.